Inovio HIV Vaccine, Which Generated Near 100% Immune Responses, Sustained Durable Memory Responses Measured One Year After The Start of Clinical Trial
May 15, 2018 08:00 ET
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., May 15, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its HIV vaccine, PENNVAX®-GP, maintained durable and robust immune responses at...
Inovio Pharmaceuticals Reports 2018 First Quarter Financial Results
May 09, 2018 16:05 ET
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., May 09, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), a late-stage biotechnology company focused on the discovery, development, and commercialization of...
Inovio Pharmaceuticals to Report First Quarter 2018 Financial Results on May 9, 2018
April 30, 2018 08:00 ET
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., April 30, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2018 first...
Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS
April 11, 2018 08:00 ET
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa. and OSLO, Norway, April 11, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and CEPI – the Coalition for Epidemic Preparedness Innovations – today announced...
Inovio Pharmaceuticals to Present at the H.C. Wainwright Annual Global Life Sciences Conference
April 02, 2018 08:00 ET
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., April 02, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. J. Joseph Kim, Inovio’s President & CEO, will provide a corporate...
Inovio Closes License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China
March 20, 2018 08:00 ET
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., March 20, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced it has closed an agreement providing ApolloBio Corp. (NEEQ:430187) with the...
Inovio Pharmaceuticals Reports 2017 Fourth Quarter and Year End Financial Results
March 14, 2018 16:05 ET
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., March 14, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the fourth quarter and year ended December 31, 2017. Total...
Inovio’s DNA Immunotherapy Demonstrates Immune Response Results Key in Treating Chronic Hepatitis B Infection
March 14, 2018 08:00 ET
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., March 14, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that interim Phase 1 results show its DNA immunotherapy designed to treat...
Inovio Pharmaceuticals to Report Fourth Quarter and Year End 2017 Financial Results on March 14, 2018
March 12, 2018 08:00 ET
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., March 12, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2017 fourth...
Inovio and The Wistar Institute Receive More Than $4.6 Million in R&D Funding to Advance Vaccines Against Tuberculosis & Malaria
February 12, 2018 08:00 ET
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the company is collaborating with The Wistar Institute to advance two novel...